A detailed history of L & S Advisors Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, L & S Advisors Inc holds 50,260 shares of BCYC stock, worth $995,650. This represents 0.16% of its overall portfolio holdings.

Number of Shares
50,260
Previous 10,190 393.23%
Holding current value
$995,650
Previous $184,000 579.89%
% of portfolio
0.16%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$16.75 - $26.1 $671,172 - $1.05 Million
40,070 Added 393.23%
50,260 $1.25 Million
Q4 2023

Feb 13, 2024

BUY
$13.29 - $22.2 $135,425 - $226,218
10,190 New
10,190 $184,000
Q4 2022

Feb 13, 2023

SELL
$20.37 - $32.9 $159,191 - $257,113
-7,815 Reduced 18.27%
34,950 $1.03 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $747,959 - $1.22 Million
42,765 New
42,765 $995,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $588M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track L & S Advisors Inc Portfolio

Follow L & S Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on L & S Advisors Inc with notifications on news.